Inventor
TAMADA KOJI
JP26 patents
⚠️ This page may combine multiple inventors who share the name “TAMADA KOJI”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
UNIV YAMAGUCHI
8 patentsUS11337997B2May 24, 2022
Immunocompetent cell and expression vector expressing regulatory factors of immune function
UNIV YAMAGUCHI5 citations81
US10906984B2Feb 2, 2021
CAR expression vector and CAR-expressing T cells
UNIV YAMAGUCHI5 citations81
US10316102B2Jun 11, 2019
Car expression vector and car-expressing T cells
UNIV YAMAGUCHI12 citations81
US11931381B2Mar 19, 2024
Immunocompetent cell and expression vector expressing regulatory factors of immune function
UNIV YAMAGUCHI3 citations72
US10781249B2Sep 22, 2020
Anti-GPC3 antibody
UNIV YAMAGUCHI2 citations71
US12129291B2Oct 29, 2024
Anti-GPC3 antibody
UNIV YAMAGUCHI0 citations60
US11718663B2Aug 8, 2023
Anti-GPC3 antibody
UNIV YAMAGUCHI0 citations60
US11617765B2Apr 4, 2023
Enhancer for T-cells or B-cells having memory function, malignant tumor recurrence inhibitor, and inducer for inducing memory function in T-cells or B-cells
UNIV YAMAGUCHI0 citations60
CYTLIMIC INC
8 patentsUS10842848B2Nov 24, 2020
Method for treating cancer by adminstering poly I:C and LAG-3-IgG fusion protein
CYTLIMIC INC2 citations69
US11304997B2Apr 19, 2022
HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell
CYTLIMIC INC0 citations60
US11491204B2Nov 8, 2022
Composition comprising poly I:C and LAG-3-IGG fusion protein
CYTLIMIC INC0 citations59
US11291718B2Apr 5, 2022
Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein
CYTLIMIC INC0 citations59
US10875900B2Dec 29, 2020
Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells
CYTLIMIC INC0 citations50
US10590179B2Mar 17, 2020
Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells
CYTLIMIC INC0 citations50
US10537626B2Jan 21, 2020
HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell
CYTLIMIC INC0 citations50
US10526388B2Jan 7, 2020
Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using the same, immunity inducer, and method for producing antigen-presenting cells
CYTLIMIC INC0 citations50
NEC CORP
3 patentsUS12448413B2Oct 21, 2025
HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell
NEC CORP0 citations61
US11618770B2Apr 4, 2023
MUC1-derived peptide, and pharmaceutical composition for treatment or prevention of cancer, immunity-inducing agent and method for manufacturing antigen presenting cell using same
NEC CORP0 citations61
US11759518B2Sep 19, 2023
Medicine for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein
NEC CORP0 citations59